World J Mens Health.  2013 Aug;31(2):83-102.

Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction

• Ryu JK
• Cho KS
• Kim SJ
• Oh KJ
• Kam SC
• Seo KK
• Shin HS
• Kim SW

Abstract

In February 2011, the Korean Society for Sexual Medicine and Andrology (KSSMA) realized the necessity of developing a guideline on erectile dysfunction (ED) appropriate for the local context, and established a committee for the development of a guideline on ED. As many international guidelines based on objective evidence are available, the committee decided to adapt these guidelines for local needs instead of developing a new guideline. Considering the extensive research activities on ED in Korea, data with a high level of evidence among those reported by Korean researchers have been collected and included in the guideline development process. The latest KSSMA guideline on ED has been developed for urologists. The KSSMA hopes that this guideline will help urologists in clinical practice.

Keyword

Erectile dysfunction; Guideline; Phosphodiesterase type 5 inhibitors

MeSH Terms

Andrology
Erectile Dysfunction
Korea
Male
Phosphodiesterase 5 Inhibitors
Phosphodiesterase 5 Inhibitors

Reference

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151:54–61.

2. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res. 2000; 12:305–311.

3. Tan HM, Low WY, Ng CJ, Chen KK, Sugita M, Ishii N, et al. Prevalence and correlates of erectile dysfunction (ED) and treatment seeking for ED in Asian Men: the Asian Men's Attitudes to Life Events and Sexuality (MALES) study. J Sex Med. 2007; 4:1582–1592.

4. Nicolosi A, Glasser DB, Kim SC, Marumo K, Laumann EO. GSSAB Investigators' Group. Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of Asian countries. BJU Int. 2005; 95:609–614.

5. Ahn TY, Park JK, Lee SW, Hong JH, Park NC, Kim JJ, et al. Prevalence and risk factors for erectile dysfunction in Korean men: results of an epidemiological study. J Sex Med. 2007; 4:1269–1276.

6. Cho BL, Kim YS, Choi YS, Hong MH, Seo HG, Lee SY, et al. Prevalence and risk factors for erectile dysfunction in primary care: results of a Korean study. Int J Impot Res. 2003; 15:323–328.

7. Cho NH, Ahn CW, Park JY, Ahn TY, Lee HW, Park TS, et al. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabet Med. 2006; 23:198–203.

8. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Mens Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin. 2004; 20:607–617.

9. Sun P, Swindle R. Are men with erectile dysfunction more likely to have hypertension than men without erectile dysfunction? A naturalistic national cohort study. J Urol. 2005; 174:244–248.

10. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ. Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006; 166:207–212.

11. Lee SH, Kim JC, Lee JY, Kim JH, Oh CY, Lee SW, et al. Effects of components of metabolic syndrome on sexual function in Korean BPH/LUTS patients. J Sex Med. 2009; 6:2292–2298.

12. Cho YG, Song HJ, Lee SK, Jang SN, Jeong JY, Choi YH, et al. The relationship between body fat mass and erectile dysfunction in Korean men: Hallym Aging Study. Int J Impot Res. 2009; 21:179–186.

13. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000; 56:302–306.

14. Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol. 1994; 140:930–937.

15. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med. 2000; 30:328–338.

16. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998; 60:458–465.

17. Shiri R, Koskimäki J, Tammela TL, Häkkinen J, Auvinen A, Hakama M. Bidirectional relationship between depression and erectile dysfunction. J Urol. 2007; 177:669–673.

18. Moreira ED Jr, Kim SC, Glasser D, Gingell C. Sexual activity, prevalence of sexual problems, and associated help-seeking patterns in men and women aged 40-80 years in Korea: data from the Global Study of Sexual Attitudes and Behaviors (GSSAB). J Sex Med. 2006; 3:201–211.

19. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003; 44:637–649.

20. Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. J Sex Med. 2009; 6:2299–2304.

21. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358:1250–1261.

22. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol. 2004; 45:123–133.

23. Finger WW, Lund M, Slagle MA. Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice. J Fam Pract. 1997; 44:33–34.

24. Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders;2007. p. 718–749.

25. Chung TG, Lee TK, Chung S, Lee MS, Kim YS, Ahn TY. The Korean version of the international index of erectile function(IIEF): Reliability and Validation Study. Korean J Urol. 1999; 40:1334–1343.

26. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999; 11:319–326.

27. Ahn TY, Lee DS, Kang WC, Hong JH, Kim YS. Validation of an abridged Korean version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Korean J Urol. 2001; 42:535–540.

28. Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology. 1995; 45:498–502.

29. Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol. 2002; 168:615–620.

30. Seftel AD. Diagnosis of erectile dysfunction. In : Porst H, Buvat J, editors. Standard practice in sexual medicine. Oxford: Blackwell Publishing;2006. p. 59–74.

31. Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am. 2001; 28:279–278.

32. Laumann EO, Paik A, Rosen RC. The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey. Int J Impot Res. 1999; 11:Suppl 1. S60–S64.

33. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract. 2001; 55:614–618.

34. DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol. 2000; 86:175–181.

35. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005; 96:313–321.

36. Meuleman EJ, Diemont WL. Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction. Urol Clin North Am. 1995; 22:803–819.

37. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Ioannidis E, Yannakoyorgos K, Kalinderis A. Hemodynamic characterization of a functional erection. Arterial and corporeal veno-occlusive function in patients with a positive intracavernosal injection test. Eur Urol. 1999; 36:60–67.

38. Wespes E, Schulman C. Venous impotence: pathophysiology, diagnosis and treatment. J Urol. 1993; 149:1238–1245.

39. Hatzichristou DG, Saenz de, Kupferman S, Namburi S, Pescatori ES, Udelson D, et al. In vivo assessment of trabecular smooth muscle tone, its application in pharmaco-cavernosometry and analysis of intracavernous pressure determinants. J Urol. 1995; 153:1126–1135.

40. Hatzichristou DG, Hatzimouratidis K, Ioannides E, Yannakoyorgos K, Dimitriadis G, Kalinderis A. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect of sexual intercourse. J Urol. 1998; 159:1921–1926.

41. Nehra A, Moreland RB. Neurologic erectile dysfunction. Urol Clin North Am. 2001; 28:289–308.

42. Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I, Fawzy A. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urol Clin North Am. 2004; 31:249–257.

43. Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I, Fawzy A. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin North Am. 2004; 31:259–273.

44. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004; 291:2978–2984.

45. Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med. 2010; 7:2201–2208.

46. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. International Society of Andrology. International Society for the Study of Aging Male. European Association of Urology. European Academy of Andrology. American Society of Andrology. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009; 55:121–130.

47. Kim MJ, Rhee Y, Seo JT, Yang DY, Moon DG, Park NC, et al. The Academic Committee of the Korean Society for the Aging Male Research. 2006 KOSAR recommendations for investigation, treatment and monitoring of LOH in males. Korean J Androl. 2008; 26:8–10.

48. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005; 63:381–394.

49. Boloña ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007; 82:20–28.

50. Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab. 2005; 90:6472–6479.

51. Rao DS, Donatucci CF. Vasculogenic impotence. Arterial and venous surgery. Urol Clin North Am. 2001; 28:309–319.

52. Wespes E, Wildschutz T, Roumeguere T, Schulman CC. The place of surgery for vascular impotence in the third millennium. J Urol. 2003; 170:1284–1286.

53. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2002; 53:Suppl 1. 61S–65S.

54. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology. 2002; 60:2 Suppl 2. 12–27.

55. Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003; 26:279–284.

56. Choi HK, Ahn TY, Kim JJ, Kim SC, Paick JS, Suh JK, et al. A double-blind, randomised-placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. Int J Impot Res. 2003; 15:80–86.

57. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003; 62:121–125.

58. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002; 168:1332–1336.

59. Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002; 25:2159–2164.

60. Choi HK, Kim JJ, Kim SC, Suh J, Park YK, Choi S, et al. A randomised, double-blind, parallel, placebo-controlled study of the efficacy and safety of tadalafil administered on-demand to men with erectile dysfunction in Korea. Korean J Urol. 2006; 47:852–858.

61. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003; 61:4 Suppl 1. 8–14.

62. Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res. 2004; 16:470–478.

63. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003; 26:777–783.

64. Chen KK, Paick JS, Ishii N. Vardenafil Study Group. The efficacy and safety of vardenafil in East Asian men with erectile dysfunction. J Sex Med. 2007; 4:753–761.

65. Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008; 65:848–854.

66. Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008; 5:946–953.

67. Park HJ, Park JK, Park K, Min K, Park NC. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J Sex Med. 2010; 7:2209–2216.

68. Paick JS, Choi HK, Kim SC, Ahn TY, Kim JJ, Park JK, et al. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Asian J Androl. 2008; 10:791–798.

69. Park HJ, Choi HK, Ahn TY, Park JK, Chung WS, Lee SW, et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med. 2010; 7:2842–2850.

70. Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, Didonato K, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012; 9:1122–1133.

71. Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, et al. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. BJU Int. 2012; 110:1801–1806.

72. Liu G, Sun X, Dai Y, Zheng F, Wang D, Huang Y, et al. Chronic administration of sildenafil modified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction. J Sex Med. 2010; 7:3868–3878.

73. Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 2008; 101:203–210.

74. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007; 19:200–207.

75. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol. 2009; 181:245–251.

76. Rubio-Aurioles E, Kim ED, Rosen RC, Porst H, Burns P, Zeigler H, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med. 2009; 6:1314–1323.

77. Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2011; 60:380–387.

78. Porst H, Rajfer J, Casabé A, Feldman R, Ralph D, Vieiralves LF, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med. 2008; 5:2160–2169.

79. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005; 2:415–425.

80. Ricardi U, Gontero P, Ciammella P, Badellino S, Valentino F, Munoz F, et al. Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med. 2010; 7:2851–2859.

81. Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol. 2008; 54:204–210.

82. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006; 332:589–592.

83. Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med. 2008; 5:1841–1865.

84. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002; 60:2 Suppl 2. 28–38.

85. Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol. 2005; 47:518–522.

86. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study. Eur Urol. 2006; 50:126–132.

87. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004; 172:658–663.

88. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol. 2006; 50:940–947.

89. Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int. 2007; 100:122–129.

90. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol. 2004; 27:4 Suppl 1. I20–I25.

91. Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002; 40:2006–2012.

92. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med. 2009; 6:658–674.

93. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res. 2009; 21:122–128.

94. Lee JY, Cho SY, Oh CY, Ha US, Lee SH, Park SY, et al. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res. 2011; 23:249–256.

95. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am. 2001; 28:335–341.

96. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997; 15:78–82.

97. Leungwattanakij S, Flynn V Jr, Hellstrom WJ. Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin North Am. 2001; 28:343–354.

98. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996; 155:802–815.

99. Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 2001; 13:317–321.

100. Soli M, Bertaccini A, Carparelli F, Gotti R, Cavrini V, Andrisano V, et al. Vasoactive cocktails for erectile dysfunction: chemical stability of PGE1, papaverine and phentolamine. J Urol. 1998; 160:551–555.

101. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991; 146:1564–1565.

102. Valdevenito R, Melman A. Intracavernous self-injection pharmacotherapy program: analysis of results and complications. Int J Impot Res. 1994; 6:81–91.

103. Bechara A, Casabé A, Chéliz G, Romano S, Rey H, Fredotovich N. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol. 1997; 157:2132–2134.

104. Kim SC, Kim DS, Kim SW, Jim JH, Kim JJ, Moon KH, et al. Multicenter study on the efficacy and safety of intracavernous 'TM' (Standro®) for the treatment of erectile dysfunction in Korean. Korean J Urol. 2003; 44:702–707.

105. McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999; 162:1992–1997.

106. Dittrich A, Albrecht K, Bar-Moshe O, Vandendris M. Treatment of pharmacological priapism with phenylephrine. J Urol. 1991; 146:323–324.

107. Molina L, Bejany D, Lynne CM, Politano VA. Diluted epinephrine solution for the treatment of priapism. J Urol. 1989; 141:1127–1128.

108. Pautler SE, Brock GB. Priapism. From Priapus to the present time. Urol Clin North Am. 2001; 28:391–403.

109. Sundaram CP, Thomas W, Pryor LE, Sidi AA, Billups K, Pryor JL. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology. 1997; 49:932–935.

110. Gupta R, Kirschen J, Barrow RC 2nd, Eid JF. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol. 1997; 157:1681–1686.

111. Vardi Y, Sprecher E, Gruenwald I. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters. J Urol. 2000; 163:467–470.

112. Paick JS, Lee KC, Kim SW, Lee C, Kim SW. Trimix intracavernosal self-injection therapy: long-term follow-up results in the patients with erectile dysfunction. Korean J Urol. 1998; 39:911–915.

113. Montague DK, Angermeier KW. Penile prosthesis implantation. Urol Clin North Am. 2001; 28:355–361.

114. Kim YD, Yang SO, Lee JK, Jung TY, Shim HB. Usefulness of a malleable penile prosthesis in patients with a spinal cord injury. Int J Urol. 2008; 15:919–923.

115. Montorsi F, Rigatti P, Carmignani G, Corbu C, Campo B, Ordesi G, et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol. 2000; 37:50–55.

116. Goldstein I, Newman L, Baum N, Brooks M, Chaikin L, Goldberg K, et al. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol. 1997; 157:833–839.

117. Kim DS, Yang KM, Chung HJ, Choi HM, Choi YD, Choi HK. AMS 700CX/CXM inflatable penile prosthesis has high mechanical reliability at long-term follow-up. J Sex Med. 2010; 7:2602–2607.

118. Carson CC 3rd. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol. 2004; 171:1611–1614.

119. Wolter CE, Hellstrom WJ. The hydrophilic-coated inflatable penile prosthesis: 1-year experience. J Sex Med. 2004; 1:221–224.

120. Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol. 2000; 163:481–482.

121. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008; 18:613–620.

122. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982; 128:492–497.

123. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983; 4:473–485.

124. Takenaka A, Tewari AK, Leung RA, Bigelow K, El-Tabey N, Murakami G, et al. Preservation of the puboprostatic collar and puboperineoplasty for early recovery of urinary continence after robotic prostatectomy: anatomic basis and preliminary outcomes. Eur Urol. 2007; 51:433–440.

125. Tewari AK, Bigelow K, Rao S, Takenaka A, El-Tabi N, Te A, et al. Anatomic restoration technique of continence mechanism and preservation of puboprostatic collar: a novel modification to achieve early urinary continence in men undergoing robotic prostatectomy. Urology. 2007; 69:726–731.

126. Lunacek A, Schwentner C, Fritsch H, Bartsch G, Strasser H. Anatomical radical retropubic prostatectomy: 'curtain dissection' of the neurovascular bundle. BJU Int. 2005; 95:1226–1231.

127. Savera AT, Kaul S, Badani K, Stark AT, Shah NL, Menon M. Robotic radical prostatectomy with the "Veil of Aphrodite" technique: histologic evidence of enhanced nerve sparing. Eur Urol. 2006; 49:1065–1073.

128. Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol. 2003; 169:1453–1457.

129. Ayyathurai R, Manoharan M, Nieder AM, Kava B, Soloway MS. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int. 2008; 101:833–836.

130. Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003; 170:1278–1283.

131. Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, Ahuja S, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol. 2004; 172:1036–1041.

132. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997; 158:1408–1410.

133. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, et al. Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008; 20:479–486.